Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics - GBI Research Reports

Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics

Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics - GBI Research Reports
Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics
Published Dec 01, 2010
124 pages — Published Dec 01, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest report, 'Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics' that provides key data, information and analysis of the major trends and issues in Personalized Medicine Market. The report provides a comprehensive insight into the role of Human Genomics and Proteomics to challenge traditional therapeutics. The report also provides a detailed analysis of market characterization of personalized medicine market in terms of its market size, segmentation by key geography types and the major market drivers and barriers. The report also talks about the patent landscape for human genomics and proteomics and provides comprehensive analysis.

Scope

The scope of the report includes:
- Detailed overview of Personalized Medicine Market in pharmaceutical industry along with their use, efficiency and limitation.
- Annualized market data from 2007 and forecast forward till 2016 along with segmentation by geography.
- Key market drivers and restraints shaping the Personalized Medicine Market.
- Competitive landscape analysis with competitive profiling of leading companies.
- Analysis of partnership deals from 2006 to 2010
- Analysis of M&A deals from 2005 to 2010 along with segmentation by value geography and companies.

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Develop better strategies for personalized medicine market research by understanding the market dynamics.
- Develop market-entry and market expansion strategies by identifying the key development area
- Understand the factors shaping the Personalized Medicine Market
- For understanding the role of Human Genomics and Proteomics to challenge traditional therapeutics.
- Identify the key players best positioned to take the advantage of the opportunities in the global market.
- Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.

  
Source:
Document ID
GBIHC044MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents46
1.1 List of Tables72
1.2 List of Figures91
2 Personalized Medicine Market: Market Overview105
2.1 Introduction102
2.1.1 Potential Applications of Personalized Medicine121
Optimization of Therapy121
2.1.1.2 Safer and Effective Drugs - Reduce Adverse Drug Reactions121
2.1.1.3 Reduce time, cost and failure rate of clinical trials 131
2.1.1.4 Preventive rather than curative approach131
2.1.1.5 Rescue drugs failing in the market131
2.2 GBI Research Report Guidance141
3 Personalized Medicine Market: Drivers and Barriers 154
3.1 Drivers 161
Increase in healthcare costs 161
3.1.2 Advantages over conventional drug discovery methods 161
3.1.3 Patient compliance161
3.1.4 Early detection of disease171
3.1.5 Better regulatory norms and validation procedures encourage growth of the personalized medicine market171
3.2 Barriers171
3.2.1 Payer Reimbursement Issues171
3.2.2 Ethical Issues171
3.2.3 Medical Information Technology181
3.2.4 Awareness Gap Lack of Physician Education and Awareness about Novel Technologies 181
3.2.5 Cumbersome and Lengthy Development Procedure Discourages Biomarker Research by the Pharmaceutical Sector181
4 Personalized Medicine Market Personalized Therapeutics and Diagnostics1961
Personalized Therapeutics Drug Profiles191
4.1.1 Herceptin (trastuzumab)191
4.1.1.1 Overview191
4.1.1.2 Efficacy201
4.1.1.3 Safety201
4.1.1.4 Pricing201
4.1.1.5 Clinical Study Details201
4.1.1.6 Clinical Study Details (Herceptin for HER2-positive stomach (gastric) cancer)211
4.1.1.7 Lifecycle Management Activities221
4.1.1.8 Drug Sales231
4.1.1.9 SWOT Analysis241
4.1.2 Erbitux (cetuximab)241
Overview 241
4.1.2.2 Efficacy 251
4.1.2.3 Safety251
4.1.2.4 Pricing251
4.1.2.5 Clinical Study Details 251
4.1.2.6 Lifecycle Management Activities251
4.1.2.7 Drug Sales262
4.1.2.8 SWOT Analysis281
4.1.3 Gleevec (imatinib)281
Overview281
4.1.3.2 Efficacy291
4.1.3.3 Safety291
4.1.3.4 Pricing291
4.1.3.5 Clinical Study Details291
4.1.3.6 Lifecycle Management Activities292
4.1.3.7 Drug Sales311
4.1.3.8 SWOT Analysis321
4.1.4 Zyprexa (olazapine)321
Overview 321
4.1.4.2 Efficacy 321
4.1.4.3 Safety 321
4.1.4.4 Pricing331
4.1.4.5 Clinical study details 331
4.1.4.6 Lifecycle Management Activities331
4.1.4.7 Drug Sales341
4.1.4.8 SWOT Analysis351
4.1.5 Lipitor (atorvastatin)351
Overview 351
4.1.5.2 Efficacy361
4.1.5.3 Safety 361
4.1.5.4 Pricing 361
4.1.5.5 Clinical Study Details361
4.1.5.6 Lifecycle Management Activities362
4.1.5.7 Drug Sales381
4.1.5.8 SWOT Analysis391
4.1.6 Celebrex (celecoxib)391
Overview 391
4.1.6.2 Efficacy 391
4.1.6.3 Safety Profile391
4.1.6.4 Pricing391
4.1.6.5 Clinical Study Details391
4.1.6.6 Lifecycle Management Activities401
4.1.6.7 Drug Sales411
4.1.6.8 SWOT Analysis421
4.1.7 Tarceva (erlotinib)421
Overview 421
4.1.7.2 Efficacy 421
4.1.7.3 Safety431
4.1.7.4 Pricing431
4.1.7.5 Clinical study details 431
4.1.7.6 Drug Sales441
4.1.7.7 SWOT Analysis451
4.1.8 Rituxan (rituximab)461
Overview 461
4.1.8.2 Efficacy 461
4.1.8.3 Safety Profile461
4.1.8.4 Pricing461
4.1.8.5 Clinical Study Details461
4.1.8.6 Drug Sales471
4.1.8.7 SWOT Analysis481
4.1.9 Plavix (clopidogrel bisulfate)491
Overview491
4.1.9.2 Efficacy491
4.1.9.3 Safety491
4.1.9.4 Lifecycle Management Activities491
4.1.9.5 Drug Sales501
4.1.9.6 SWOT Analysis511
4.1.10 Risperdal (risperidone)511
Overview511
4.1.10.2 Efficacy521
4.1.10.3 Safety521
4.1.10.4 Clinical Study Details521
4.1.10.5 Lifecycle Management Activities521
4.1.10.6 Drug Sales531
4.1.10.7 SWOT Analysis541
4.1.11 Vectibix (Panitumumab)541
4.1.11.1 Overview541
4.1.11.2 Efficacy541
4.1.11.3 Safety551
4.1.11.4 Pricing551
4.1.11.5 Clinical Study Details551
4.1.11.6 Lifecycle Management Activities551
4.1.12 Coumadin (Warfarin)561
Overview 561
4.1.12.2 Efficacy 561
4.1.12.3 Safety 561
4.1.12.4 Pricing561
4.1.12.5 Clinical Study Details 561
4.1.13 Iressa (Gefitinib)571
Overview571
4.1.13.2 Efficacy571
4.1.13.3 Safety 581
4.1.13.4 Pricing581
4.1.13.5 Clinical study details581
4.1.13.6 Lifecycle Management Activities581
4.1.14 Sprycel591
Overview591
4.1.14.2 Efficacy591
4.1.14.3 Safety601
4.1.14.4 Lifecycle Management Activities601
4.1.15 Camptosar611
Overview611
4.1.15.2 Efficacy611
4.1.15.3 Safety611
4.1.15.4 Clinical Study Details611
4.1.15.5 Pricing611
4.1.15.6 Lifecycle Management Activities611
Companion Diagnostics622
4.2.1 Selected Companion Diagnostics Employed in Personalized Healthcare641
4.2.1.1 AmpliChip CYP450641
Oncotype Dx641
4.2.1.3 MammaPrint641
4.2.1.4 Theros breast cancer index 641
4.2.1.5 Mammostrat641
HercepTest 651
4.2.1.7 DakoCytomation EGFR pharmDx651
4.2.1.8 eQ-PCR LC Warfarin Genotyping Kit.651
4.2.1.9 PGx Predict:Rituximab651
4.2.1.10 PhyzioType PIMS (Psychotropic-Induced Metabolic Symptoms)661
4.2.1.11 THERO CancerTYPE ID661
4.2.1.12 CupPrint661
4.2.1.13 HER2 FISH pharmDx Kit661
4.2.1.14 AlloMap gene profile661
4.2.1.15 Target GI Test671
4.3 Biomarkers 671
4.3.1 Biomarkers in Cancer Research681
4.3.2 Market Size and Forecasts691
Segmentation by Indication701
4.3.3.1 Breast cancer711
4.3.3.2 Prostate cancer721
4.3.3.3 Lung cancer731
4.3.3.4 Colorectal cancer741
Cervical cancer751
4.3.3.6 Head and neck cancer761
4.3.3.7 Pancreatic cancer771
4.3.3.8 Ovarian cancer781
4.3.3.9 Stomach cancer791
5 Personalized Medicine Market: Selected Pipeline Product Profiles808
PF-4948568 (Pfizer)801
5.1.1 Overview801
5.1.2 Mechanism of Action801
5.1.3 Clinical Study Details801
5.2 PF-02341066 + Erlotinib (Pfizer)811
5.2.1 Overview811
5.2.2 Mechanism of Action811
5.2.3 Clinical study details811
5.3 PF-299804 (Pfizer)821
Overview 821
5.3.2 Mechanism of action821
5.3.3 Clinical study details821
5.4 CEP-701 (Cephalon Inc.)831
5.4.1 Overview831
5.4.2 Mechanism of action831
5.4.3 Clinical study details841
TBR-652 (Tobira Therapeutics, Inc)841
5.5.1 Overview841
5.5.2 Mechanism of action841
5.5.3 Clinical study details851
Brivanib (Bristol-Myers Squibb)851
5.6.1 Overview851
5.6.2 Mechanism of action851
5.6.3 Clinical study details861
5.7 Ipilimumab (Bristol-Myers Squibb)861
5.7.1 Overview861
5.7.2 Mechanism of Action861
5.7.3 Clinical Study Details861
BiovaxID (Accentia Biopharmaceuticals, Inc.)871
5.8.1 Overview871
5.8.2 Mechanism of Action871
5.8.3 Clinical Study Details871
6 Personalized Medicine Market: Research Trends in Personalized Medicine881
7 Personalized Medicine Market: Competitive Landscape8928
Competitive Profiling891
7.2 Clarient, Inc.891
7.2.1 Business Description891
7.2.2 Pipeline901
7.2.3 Major Products901
7.2.3.1 Clarient breast cancer test901
7.2.3.2 Head and neck cancer assay901
7.2.3.3 Insight Dx colon cancer marker901
7.2.3.4 Insight Dx Leukemia marker901
7.2.3.5 Mammostrat Basal901
7.2.4 Partnership and Merger and Acquisition (M&A) Deals911
7.3 Qiagen N.V.921
7.3.1 Business Description921
7.3.2 Pipeline921
7.3.3 Major Products921
7.3.3.1 ABL Assay921
7.3.3.2 Artus CMV (cytomegalovirus) assay921
7.3.3.3 Artus EBV (Epstein-Barr virus)931
7.3.3.4 Artus HSV 1/2 RG 6000931
7.3.3.5 B-Raf Test-Colon Cancer931
7.3.4 Partnership and M&A Deals942
7.4 Laboratory Corporation of America Holdings 961
7.4.1 Business Description961
7.4.2 Pipeline961
7.4.3 Major Products961
7.4.3.1 OvaSure961
7.4.4 Partnership and M&A Deals972
7.5 bioMerieux S.A.991
7.5.1 Business Description991
7.5.2 Pipeline991
7.5.3 Major Products991
7.5.3.1 Annexin A3 Test991
7.5.3.2 Breast cancer theranostic assay991
7.5.3.3 Point of care testing device991
7.5.4 Partnership and M&A Deals1002
7.5.5 Partnership and M&A Deals1021
7.6 Pfizer1021
7.6.1 Business Overview 1021
7.6.2 Partnership and M&A Deals1031
7.6.2.1 Wyeth Expands Co-Development Agreement With Caprion Pharmaceuticals June 20051031

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics" Dec 01, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Personalized-Medicine-Market-Advances-in-Human-Genomics-and-Proteomics-to-Challenge-Traditional-Therapeutics-2115-115>
  
APA:
GBI Research Reports. (2010). Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics Dec 01, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Personalized-Medicine-Market-Advances-in-Human-Genomics-and-Proteomics-to-Challenge-Traditional-Therapeutics-2115-115>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.